Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DEMECAN is a leading German pharmaceutical company specializing in the entire value chain of medical cannabis, from cultivation and processing to distribution. As one of the few entities licensed by the Federal Institute for Drugs and Medical Devices (BfArM) to produce medical cannabis in Germany, the company operates a state-of-the-art GMP-certified manufacturing facility in Saxony. Their product portfolio includes high-quality cannabis flowers, full-spectrum extracts, and Dronabinol, aimed at treating chronic pain and other complex conditions. DEMECAN focuses on ensuring a reliable supply of medical-grade cannabinoids to pharmacies and wholesalers across the European market. The company is vertically integrated, combining pharmaceutical expertise with advanced indoor cultivation technology to meet strict regulatory standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DEMECAN.